Dr. Reddy’s launches authorized generic version of Imitrex® Tablets

Company Briefs

New Delhi, November 24, 2008

Dr. Reddy’s Laboratories (NYSE:RDY) today announced that it has launched the authorized generic version of GlaxoSmithKline’s Imitrex® (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr. Reddy’s is the first company to launch an authorized generic version of Imitrex® tablets in the US market.

In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex® tablets. The specific financial terms and conditions of the settlement have not been disclosed.

GlaxoSmithKline Imitrex® tablets, which are indicated for the acute treatment of migraine attacks in adults, had U.S. sales of $1.29 billion for the 12 month period ending December, 2007 according to IMS.

For further information, please contact:

Genesis Burson- Marsteller

Mansi Chugh

Email : mansi.chugh@bm.com

Tel: + 91 124 4044999-142